The aim of the study was to investigate the antithrombotic efficiency, safety and tolerance of Lospirintm in patients with coronary artery disease. The study involved 50 patients (32 men and 18 women) aged 40-65 years with disease duration from 3 to 27 years, receiving daily one tablet of Lospirintm (75 mg) for 28 days as an antiplatelet agent in addition to basic therapy. General clinical data, hemodynamic parameters, laboratory results of blood tests, urine and agregant state of blood plasma were assessed. During the period of drug application side effects/reactions were not registered. Tolerance of Lospirintm was satisfactory in 100% of patients. Drug intake for 28 days gave good antiplatelet results in 90% of patients with coronary artery disease

Hrytsenko, V. I.

Khomaziuk, T. A.

Kryzhanovska, S. I.

Levykh, А. Е.

Novozhenina, L. I.

English

Khomaziuk, T. A. (T)

Novozhenina, L. I. (L)

Levykh, А. Е. (А)

Kryzhanovska, S. I. (S)

Hrytsenko, V. I. (V)

Neliti

The Study of Antithrombotic Efficacy, Safety and Tolerability of Aspirin Generic in Patients with Coronary Heart Disease.

Наукова періодика України

3713/  XV I / 316. Hank JuoS, Lin H, Rundek T, Sabala E. Genetic and Environmental Contributions to Carotid Intima-Me-dia thickness and obesity phenotypes in the Northern Manhattan Family Study. Stroke. 2004;35:2243–7.  17. Joseph L, Izzo Jr. Hypertension primer. The es-sentials of high blood pressure. Basic science, population science, and clinical managemen. 2012. 18. Nilsson Peter. Early vascular aging as a clinical model for understanding cardiovascular risk. Internal Me-dicine. 2008;5–6(11–12):112–7.  19. Ratchford E, Lorenzo VD, McClendon MS. Short-Term Effect of Atorvastatin on Carotid Artery Elasticity. A Pilot Study. Stroke. 2011;42:3460–4.  20. Stein JH, Korcarz CE, Hurst RT. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Sta-tement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine .Journal of the American Society of Echocardiography. 2008;48:93–111.   616.12-005.4:612.115:615.225 . . ,. . ,. . ,. . ,. .,C « »( . – . . , . . . ),( . – . . , . . . ). , 9, , 49044, SE "Dnipropetrovsk medical academy Ministry of Health of Ukraine" Dzerzhinsky Str., 9, Dnipropetrovsk, 49044, Ukraine e-mail: m.mila.5@mail.ru : , ,Key words: coronary artery disease, antithrombotic agent, lospirin . , -. . . , . . , . . ,. . , . . . ,.  50 (32  18 )  40-65  3  27 ,  28 ,,  1  (75 ) ., , ,. /.  100% . 28  90% .Abstract. The study of antithrombotic efficacy, safety and tolerability of aspirin generic in patients with coronary heart disease. T.A. Khomaziuk, L.I. Novozhenina, . . Levykh, S.I. Kryzhanovska, V.I. Hrytsenko. The aim of the study was to investigate the antithrombotic efficiency, safety and tolerance of Lospirintm in patients with coronary artery disease. The study involved 50 patients (32 men and 18 women) aged 40-65 years with disease duration from 3 to 27 years, receiving daily one tablet of Lospirintm (75 mg) for 28 days as an antiplatelet agent in addition to basic therapy. General clinical data, hemodynamic parameters, laboratory results of blood tests, urine and agregant state of blood plasma were assessed. During the period of drug application side effects/reactions were not registered. Tolerance of Lospirintm was satisfactory in 100% of patients. Drug intake for 28 days gave good antiplatelet results in 90% of patients with coronary artery disease. 38- ( ), -- -.- (Antithrombotic Trialists’ Collabo-ration, 2009),  16  17 , --, , - ( -, )  20%,  –  31%, , , – 13%,  –  22%, - 9%  –  19% [14].  -, (  18%) [4].   CAPRIE (1996), - 20 . , --,(325 / ) , - [15].  ( - IA) -.--, ,-. 15  « -».  « » -, , -, -, ,,  « » ( -) ., -,( , -, - « »,  75  1 -).-, , -- [1].   50 - (32  18 ) 40-65 - 3  27 ,  26 (52%) –  ( )-.: III II , 1-2  (  18-  – 1  (36%)  8-  (16%) – 2 ).  4- (8%) -. - (2008) -436 .( : / -, , -)  2-.-IV NYHA, ,, -, ,,, --., -, , -,-.,-- . 6 (12%) , ,3913/  XV I / 3 30 (60%) – ,.,436  ( / -II, , - , ,.). - 2- .-1 - -  1 , ,  28 ., -,. , 7-  ( -2)  28-  ( -3).-, - ( ), - ( ), ,, - ( -; ,, - [8]; ;), -2 (11- -- 2),-.- «StatPlus 2006 Professional»  t- [9].  -: - III - 1-2 . -38 ,  - 7,  5 – .- - 22-  (44%) , - 4-  (8%) ,  11  - .  – 27 ,  – -.--.- ( .1). 1   (M±m)  (n=50) , , , ±m 2,43 0,07 , %, ±m 84,18 14,59 , ., ±m 8,53 0,20  30 , %/ ., ±m 8,89 1,90 , ./ , ±m 182,7 14,98 , %, ±m 184,94 8,05 179,9  6,95 / / . 11- - 2 - 659,2  54,28 / .- NYHA  (36  – 72%), - -, ,, -. -. 1. 40*00,511,522,533,5 7  28 . 1.  III :  * – p<0,05 --- (4,6 . .,  2,6 . ).-  8- (16%) -.-- 28- -.- ( . 2). ,- 28-. 2   (n=50) , / /, ±m 179,9 6,95  28 , ±m 147,6 3,98 %  -17,92 , 0,00023 -, -,  11- -- 2. - 3  4. 4113/  XV I / 3 3   (n=50), ., ±m 2,43 0,07  28 , ±m 4,00 0,24 %  +64,83 , 0,0000006 , - 1 . (75 )28 1,65 ,,. 4  ,(n=50) 7  28 ±m ±m % . ±m %.84,18 14,59 32,55 5,72 -61,3 0,001 25,35 10,44 -69,9 0,001 , % 75,94 17,21 43,25 5,72 -43,0 0,02 38,16 2,15 -49,7 0,007 28,89 3,9 9,89 1,41 -65,8 0,003 7,16 1,65 -75,2 0,001 , %/46,18 4,79 27,22 2,38 -41,1 0,03 23,37 2,9 -49,4 0,01 8,53 0,21 8,24 0,43 -3,41 0,55 8,33 0,49 -2,34 0,68 ,5,08 0,71 6,06 0,49 +19,2 0,27 7,47 0,49 +46,9 0,009 , % 2,08 0,32 1,86 0,43 -10,7 0,68 0,71 0,15 -65,8 0,001 /182,7 14,98 194,7 11,04 +6,59 0,52 164,49 8,88 -9,98 0,31 , % 184,9 8,05 188,1 8,29 +1,74 0,79 189,47 16,22 +2,45 0,81 :  – - ; I  – - .42--., - (  -75%)  28-, - -- (  -50%), -, , , --. ( -),,-. 65% ., --2 , 4  50-80%.  10% -,.--.- -.-2  – 11-- 2 –  ( .5),- 80%. -2 , -,,, -- ( , , -),, -, . . -. 5-  (10%) --, , , -. -. 5   11-- 2 (n=50) 11- - 2,/, ±m 659,2 54,28  28 , ±m 128,3 14,10 % -80,54 ,  < 0,0001 , -- 28 - 90% . 30 (60%) -.-/ -.1. – --.2. --,,-.3..4313/  XV I / 31. . . - / . .  // .- .  « -». – .: , 2001. – . 17 – 29.  2. . . / . . , . . -. – .: , 2001. – 285 .3. . . , -, : ,, ,  / . . , . . -, . . . – .: , 2004.–576 .4. . . : / . . , . . // ’ . – 2007. –  7. – .48-49.  5. . . - / . . -, . .  // . . . – 2002. –  5. – . 107-112. 6. . . / . .  // . . . – 2002. –  2. – . 15-31. 7. . . -- / . . , . . - // . . . – 2005. –  8. – . 65-67. 8. / . . , . . , . .[ .]. – , 1980. – 308 .9. . . :. – 2- ., . / . . , . . -. – : - , 1997. - 396 .10. - - / . . , . . -, . .  [ .]. – ., 2001. – 29 .11. -: .- . . – ,2000. – 47 .12. . . / . . ,. . , . . . – .: , 2001. – 426 .13. . : - (ESC-2012) 25-29 , . ,  // ’ . – 2012. –  6(26). – .6.  14. Antithrombotic Trialists' Collaboration. Collabo-rative meta_analysis of  randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. – 2002. – Vol. 324. – P. 71-86. 15. CAPRIE steering committee. A randomised, blin-ded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) // Lancet. – 1996. – Vol. 348. – P. 1329–39. REFERENCES1. Alyab'eva VM. The requirements for clinical trial protocol. Proceedings of the Workshop «Clinical trials of medicines and pharmacovigilance in Ukraine». Kiev: Avitsenna. 2001;17-29. 2. Barkagan ZS, Momot AP. Diagnosis and treat-ment of hemostatic disorders controlled. Moscow: N'yu-diamed; 2001:285. 3. Bratus' VV, Shumakov VA, Talaeva TV. Athero-sclerosis, coronary heart disease, acute coronary syn-drome: pathogenesis, diagnosis, clinical features, treat-ment.  Kiev: Chetverta khvilya; 2004:576. 4. Voronkov LG, Koval' EA. Aspirin: high standards of antiplatelet therapy. Zdorov’ya Ukra ni. 2007;7:48-49.  5. Voronkov LG, Tkach NA. Thromboembolic events in patients with heart failure. Ukr. kard ol. zhurn. 2002;5:107-12. 6. Gribauskas PS. Anticoagulants of indirect action. Ukr. kard ol. zhurn. 2002;2:15-31. 7. Efremova OA, Gun'ko IN. Association between coagulation and endothelial dysfunction in acute coronary syndrome. Ukr. terapevt. zhurn. 2005;8:65-67. 8. Baluda VP, Barkagan ZS, Gol'dberg ED etc. Laboratory Methods of hemostasis. Tomsk; 1980:308.  9. Peregudov FI, Tarasenko FP. Fundamentals of Systems Analysis: Studies. 2nd edition, enlarged. Tomsk: NTL; 1997:396. 10. Berkovskiy AL, Vasil'ev SA, Zherdeva LV, etc. Handbook for the Study of adhesion-platelet aggregation. Moscow; 2001:29. 11. Problems and prospects for the use of platelet agregatometrii methods in clinical practice.  Proceedings of the conference. Minsk; 2000:47. 12. Stefanov AV, Mal'tsev VI, Efimtseva TK. Guide-lines for clinical trials of drugs. K.: Avitsenna; 2001:426.  13. Tereshchenko A. Aspirin: the news of the Congress of the European Society of Cardiology (ESC-2012) 25-29 August, Munich, Germany . Zdorov’ya Ukra ni. 2012;6(26):6.  14. Antithrombotic Trialists' Collaboration. Collabo-rative meta_analysis of  randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. 15. CAPRIE steering committee. A randomised, blin-ded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-39. 

The study of antithrombotic efficacy, safety and tolerability of aspirin generic in patients with coronary heart disease.

https://www.neliti.com/publications/355266/the-study-of-antithrombotic-efficacy-safety-and-tolerability-of-aspirin-generic

The study of antithrombotic efficacy, safety and tolerability of aspirin generic in patients with coronary heart disease.

Abstract

Similar works

Full text

Available Versions

Neliti

Наукова періодика України